Gatehouse Bio

Waltham, US · Founded 2017 · Delaware corporation · 1 known investors

Gatehouse Bio develops AI-powered therapeutics for pulmonary, cardiac, neurological, and autoimmune diseases by decoding small RNAs using their Code-Breaker platform to design precision medicine treatments.

AI & Machine LearningBiotechMedical Devicesin /gatehouse-bio

Founders & leadership

Neal FosterExecutive Officer, Director

David W. Salzman, Ph.D.Executive Officer, Director

Investors · 1

Claritas CapitalNashville · $2M – $5M

Reported raises · per SEC filings

Form D private placements

▶$5.4MraisedJan 2021 · 28 investors · Biotechnology

Rule 506(b)

Officers, directors & promoters on the filing

Neal FosterExecutive Officer, Director
David W. Salzman, Ph.D.Executive Officer, Director

Offering amount: $5.4M
Amount sold: $5.4M
First sale: Dec 2020
Incorporated: Corporation, Delaware, 2017
Federal exemptions: 06b

Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.